Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribaxamase (Primary) ; Ceftriaxone; Macrolides
Indications Clostridium difficile infections
Focus Proof of concept; Therapeutic Use
Sponsors Synthetic Biologics; Theriva Biologics

Most Recent Events

22 Feb 2018 According to a Synthetic Biologics media release, the company presented additional supportive results regarding several exploratory endpoints from this trial in 4Q 2017.
01 Nov 2017 According to a Synthetic Biologics media release, the company expects to share additional results regarding several exploratory endpoints in the fourth quarter of 2017.
08 Oct 2017 Results presented at the IDWeek 2017

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com